Staff editor
Nigel Titford, CEO at Biogaia Pharma, discusses the strategic considerations and challenges involved in working across both the dietary supplement and pharmaceutical sectors.
Industry
Sponsored by
In July 2024, the journal Frontiers in Microbiology presented a groundbreaking method that overcomes this hurdle: the Flow-FISH method.
On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.
Lonza's capsules ensures targeted intestinal delivery enhancing stability and therapeutic efficacy for LBPs and pharmaceutical applications.
Cmbio announces a strategic partnership with Nimble Science to deliver first in class high-quality, multi-omic data insights from the small intestine.
Nicola Segata, from University of Trento, investigates the intricate links between diet, microbiome composition, and cardiometabolic outcomes.
Clara Delaroque, from Institut Pasteur (France), emphasizes the critical interplay between early-life microbiota and host health, specifically how the use of common food additives impacts the susceptibility to diseases later…
The acquisition will enhance its ability to address the needs of a growing market, empowering researchers and industries worldwide.
The live biotherapeutics market is forecasted to exceed $4 billion by 2030, driven by advancements like MaaT013.
Its emergence in the respiratory health sector represents a paradigm shift, offering promising avenues for innovation and investment.
